Developing ERα‐selective agonists with skeletal muscle tissue specificity would help avoid systemic side effects mediated by ERα activation, thus advancing the development of small molecule drugs for skeletal muscle regeneration in DMD. The gene discussed is ESR1; the disease is Duchenne muscular dystrophy.